Loading…
Spanish pharma company making injectable drugs (heparins) and providing fill-finish manufacturing, including for Moderna's vaccines.
Spanish pharma company making injectable drugs (heparins) and providing fill-finish manufacturing, including for Moderna's vaccines.
Pays its way from heparin sales plus contract manufacturing for other companies' injectables, Moderna among them. Its long-acting risperidone technology is licensed to Teva, which sells it in the US as Uzedy, so Rovi receives royalties and milestones rather than product sales. The López-Belmonte family controls the company.
In one line: A smaller Catalent/injectable-drug specialist.
Moat: narrow (process know-how, regulatory licence, customer qualification). Sterile-injectable and fill-finish expertise plus regulatory approvals are hard to replicate quickly.
Headquarters: Madrid, Spain · Founded: 1946 · Employees: 2,232
Size Laboratorios Farmaceuticos Rovi (ROVI.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $3.89B, the 32nd largest of 97 Spain companies the cockpit tracks. Shares closed at €68.60 on 6 Nov 2026.
Performance Over six months the shares gained 15.5%, against +2.0% for the median peer and +8.2% for the Spain market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 3.2% over the last twelve months (peer median +5.4%); the operating margin is 19.5% (peer median 15.7%).
Valuation It trades at 22.3× forward earnings against a peer median of 18.7× (6th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.3 points above its cost of capital (5.6% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €773M | €743M | €764M | €830M | €818M |
| Revenue growth | — | -3% | -8% | +1% | — |
| Gross profit | €478M | €452M | €450M | €464M | €497M |
| EBITDA | €184M | €204M | €207M | €244M | €277M |
| Net income | €185M | €140M | €137M | €170M | €200M |
| Free cash flow | €178M | €120M | €77.5M | €60.6M | €187M |
| Capital expenditure | €77.4M | €67.8M | €62.2M | €55.2M | €51.4M |
| Total debt | €108M | €137M | €126M | €65.4M | €72.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Laboratorios Farmaceuticos Rovi ROVI.MC | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
| Gerresheimer GXI.DE | $1.21B | +24% | +9% | -4% | 18.0× | 55.8% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | $1.88B | -13% | -6% | 8% | 22.5× | 0.1% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| Siegfried SFZN.SW | $3.98B | -10% | +4% | 16% | 17.8× | n/a |
| Samsung Biologics 207940.KS | $53.7B | +3% | -20% | 43% | 38.7× | 9.6% |
| Fresenius SE & Co. KGaA FRE.DE | $32.8B | +34% | +6% | 10% | 14.5× | 8.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ROVI.MC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.0% | +5.8% | 4th highest of 21 |
| 6-month return | +15.5% | +2.0% | 4th highest of 20 |
| Distance from 52-week high | -20.9% | -23.8% | 9th highest of 21 |
| Revenue growth (TTM) | +3.2% | +5.4% | 9th lowest of 20 |
| Operating margin | 19.5% | 15.7% | 6th highest of 18 |
| Forward P/E | 22.3× | 18.7× | 6th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 0.7% | 8th most demanding of 16 |
| Growth delivered (Del g) | +12.1% | +6.2% | 4th highest of 16 |
| Hurdle (Req g minus delivered) | -10.6 pp | -8.3 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +10.3 pp | +7.6 pp | 5th highest of 18 |
| EV / EBITDA | 18.8× | 12.6× | 4th most expensive of 9 |
| Net debt / EBITDA | -0.1× | -0.5× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |